• 1
    Olsen CO, McCabe RPJr. The immunology of inflammatory bowel disease. In: KirshnerJB, ShorterRG, eds. Inflammatory bowel disease. Baltimore: Williams & Wilkins, 1995; 20351.
  • 2
    Schreiber S. Inflammatory bowel disease: immunological concepts. Hepato-Gastroentrol 2000; 47:1528.
  • 3
    Gotteland M, Lopez M, Munoz C et al. Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig Dis Sci 1999; 44:8305.
  • 4
    Funakoshi K, Sugimuna K, Anezaki K, Bannai H, Ishizuka K, Asakura H. Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn’s disease and ulcerative colitis. Digestion 1998; 59:738.
  • 5
    Christ AD, Stevens AC, Koeppen H et al. An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn’s disease. Gastroenterology 1998; 115:30713.
  • 6
    Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90:324587.
  • 7
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:24552.
  • 8
    Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000; 20:75162.
  • 9
    Ikeda Y, Akbar SMF, Matsui H, Onji M. Characterization of antigen-presenting dendritic cells in the peripheral blood and in colonic mucosa in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13:84150.DOI: 10.1097/00042737-200107000-00013
  • 10
    Murakami H, Akbar SMF, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis; clinical implications and pathogenic significance. Eur J Clin Invest 2001; 31:33743.
  • 11
    Yamamoto K, Akbar SMF, Masumoto T, Onji M. Increased nitric oxide production by antigen presenting dendritic cells is responsible for low allogenic mixed leukocyte reaction (MLR) in primary biliary cirrhosis. Clin Exp Immunol 1998; 114:94101.
  • 12
    Bueno C, Almeida J, Alguero MC et al. Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: comparative analysis of different stimuli, secretion-blocking agents and induction period. Cytometry 2001; 46:3340.
  • 13
    Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med 2000; 32:55260.
  • 14
    Bloom BR, Bennet B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153:802.
  • 15
    Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179:1895902.
  • 16
    Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB 1996; 10:160713.
  • 17
    Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, Strober W. Regulation of T-cell apoptosis in inflammatory bowel diseases: to die or not to die, that is the mucosal question. Trends Immunol 2001; 22:216.
  • 18
    Bell SJ, Rigby R, English N et al. Migration and maturation of human colonic dendritic cells. J Immunol 2001; 166:495867.
  • 19
    Abe R, Peng T, Sailors J, Bucala R, Metz CN. Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 2001; 166:74753.
  • 20
    Makita H, Nishimura M, Miyamoto K et al. Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998; 158:5739.
  • 21
    Kobayashi S, Nishihira J, Watanabe S, Todo S. Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with Bacille Calmette-Guerin and lipopolysaccharide. Hepatology 1999; 29:17529.